• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Acumen Pharmaceuticals (ABOS)

Common Shares
Sell: $0.226|Buy: $0.23|Change: 2.08 (-90.83%)

Open 

$0.3444

Previous close 

$2.29

Trade high 

$0.352

Volume 

68,104,973

Year high 

$3.60

Year low 

$0.2092

Dividend yield 

–

Market capitalisation 

$15.20 mn

P/E ratio 

3.16

ISIN 

US00509G2093

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Performance 31/10/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Acumen Pharmaceuticals- 90.83
More...

Company profile

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, isa subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.